palbociclib,ribociclib
Novartis,Pfizer
['breast', 'novartis']
at #esmo22, learn more about a multicenter, open-label phase iii head-to-head study comparing two cdk4/6 inhibitors in hr+/her2- #advancedbreastcancer patients with her2-enriched disease. 
Committed to providing medical & scientific disease education information to healthcare professionals. See our community guidelines: https://t.co/pj8hG1sQAu